Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: updated efficacy and safety results from VARGADO Cohort C

被引：0
|
作者：
Grohe, C. [1 ]
Wehler, T. [2 ]
Dechow, T. [3 ]
Henschke, S. [4 ]
Schuette, W. [5 ]
Dittrich, I [6 ]
Hammerschmidt, S. [7 ]
Mueller-Huesmann, H. [8 ]
Schumann, C. [9 ]
Krueger, S. [10 ]
Atz, J. [11 ]
Kaiser, R. [11 ]
机构：
[1] Evangel Lung Clin, Dept Pneumol, Berlin, Germany
[2] Evangel Krankenhaus Hamm GmbH, Hamm, Germany
[3] Oncol Haematol Grp Practice, Ravensburg, Germany
[4] Saarland Univ Hosp, Innere Med 5, Med Klin, Homburg, Germany
[5] Krankenhaus Martha Maria Halle Dolau, Halle An Der Saale, Germany
[6] Lungenklin Lostau, Lostau, Germany
[7] Klinikum Chemnitz gGmbH, Dept Internal Med, Chemnitz, Germany
[8] Bruderkrankenhaus St Josef, Klin Hamatol & Onkol, Paderborn, Germany
[9] Klinikverbund Allgau, Clin Pneumol Thorac Oncol Sleep & Resp Med, Kempten, Germany
[10] Florence Nightingale Hosp, Dept Pulmonol Cardiol & Internal Intens Care, Dusseldorf, Germany
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs, Ingelheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V238
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [31] Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Zhang, Xiaojian
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 577 - 577
  • [32] Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
    Cortellini, A.
    Ricciuti, B.
    Facchinetti, F.
    Alessi, J. V. M.
    Venkatraman, D.
    Dall'Olio, F. G.
    Cravero, P.
    Vaz, V. R.
    Ottaviani, D.
    Majem, M.
    Piedra, A.
    Sullivan, I
    Lee, K. A.
    Lamberti, G.
    Hussain, N.
    Clark, J.
    Bolina, A.
    Barba, A.
    Benitez, J. C.
    Gorria, T.
    Mezquita, L.
    Hoton, D.
    Nana, F. Aboubakar
    Besse, B.
    Awad, M. M.
    Pinato, D. J.
    ANNALS OF ONCOLOGY, 2021, 32 (11) : 1391 - 1399
  • [33] The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
    Xu, Zhiqiao
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) plus docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy
    Grohe, C.
    Wehler, T. C.
    Henschke, S.
    Dittrich, I.
    Hammerschmidt, S.
    Aulmann, C.
    Dechow, T. N.
    Schiefer, C.
    von der Heyde, E.
    Schuette, W.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1072 - S1073
  • [35] Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy
    Masetti, Michael
    Al-Batran, Salah-Eddin
    Goetze, Thorsten O.
    Thuss-Patience, Peter
    Knorrenschild, Jorge Riera
    Goekkurt, Eray
    Folprecht, Gunnar
    Ettrich, Thomas Jens
    Lindig, Udo
    Luley, Kim Barbara
    Pink, Daniel
    Dechow, Tobias
    Sookthai, Disorn
    Junge, Sabine
    Loose, Maria
    Pauligk, Claudia
    Lorenzen, Sylvie
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (12) : 2142 - 2150
  • [36] Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
    Zhao, Shuang
    Xian, Xinghong
    Tian, Panwen
    Li, Weimin
    Wang, Ke
    Li, Yalun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    LUNG CANCER, 2024, 194
  • [38] Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Suzuki, S.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 128 - 128
  • [39] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
  • [40] Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
    Kozloff, M.
    Hainsworth, J.
    Badrinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Suzuki, S.
    Sarkar, S.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
12345